Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beamion PANTUMOR-1 zongertinib in advanced HER2-altered solid tumors
NL-OMON59779Phase 2Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zongertinib in Nonhematologic neoplasms, sponsored by Boehringer Ingelheim. Primary endpoint: Objective response. Started Oct 2024; status: recruiting.
02
Drugs
zongertinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON59779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59779.